Association between P2Y12 inhibitor reloading and in-hospital outcomes for patients with non-ST-segment elevation acute coronary syndrome already on chronic P2Y12 receptor inhibitors therapy in China: findings from the CCC-ACS (improving care for cardiovascular disease in China-acute coronary syndrome) project

被引:67
|
作者
Wang, Yintang [1 ]
Geng, Yu [1 ]
Zhang, Ou [1 ]
Xu, Qin [2 ,3 ]
Xue, Yajun [1 ]
Zhou, Boda [1 ]
Zhang, Ping [1 ]
Li, Aihua
Li, Bao
Xu, Biao
Han, Guangshu
Li, Bin
Liu, Bin
Wang, Bin
Fu, Bing
Yu, Bo
Yang, Bosong
Luo, Caidong
Wang, Changqian
Liu, Changyong
Liang, Chuanliang
Gao, Chuanyu
Lai, Chunlin
Wang, Chuntong
Zhang, Chunyan
Wu, Chunyang
Zhang, Congliang
Bin, Cui
Huang, Lan
Peng, Daoquan
Xu, Dawen
Wu, Di
Zhu, Dongmei
Chai, Dongsheng
Li, Dongyan
Tang, Fakuan
Xiao, Jun
Zhao, Fang
Huang, Fangfang
Meng, Fanju
Li, Fengwei
Gan, Fudong
Xu, Gang
Sang, Gengsheng
Ma, Genshan
Zhang, Guixia
Tao, Guizhou
Li, Guo
Chen, Guoduo
Xin, Guoqin
机构
[1] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Cardiol, 168 Litang Rd, Beijing 102218, Peoples R China
[2] Capital Med Univ, Beijing Tiantan Hosp, China Natl Clin Res Ctr Neurol Dis, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
关键词
P2Y12 receptor inhibitors; Non-ST-segment elevation acute coronary syndrome; Loading dose; Outcome; Therapy; DUAL ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; EUROPEAN-SOCIETY; ARTERY-DISEASE; FOCUSED UPDATE; 2017; ESC; CLOPIDOGREL; ASPIRIN; ANGIOPLASTY; GUIDELINES;
D O I
10.1186/s40001-023-01025-6
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background The association between P2Y12 receptor inhibitors reloading and in-hospital outcomes in non-ST-segment elevation acute coronary syndrome (NSTEACS) patients who were on chronic P2Y12 receptor inhibitors therapy remained underdetermined.Methods The Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome (CCC-ACS project) is a national registry active from November 2014 to December 2019. 4790 NSTEACS patients on chronic P2Y12 receptor inhibitors therapy were included. Cox proportional hazard models, Kaplan-Meier curves, and subgroup analyses were conducted.Results The NSTEACS patients who received reloading of P2Y12 receptor inhibitors were younger and had fewer comorbid conditions. The reloading group had a lower risk of major adverse cardiac events (MACE) (0.51% vs. 1.43%, P = 0.007), and all-cause death (0.36% vs. 0.99%, P = 0.028), the risks of myocardial infarction and major bleeding were not significantly different between patients with and without reloading. In survival analysis, a lower cumulative risk of MACE could be identified (Log-rank test, P = 0.007) in reloading group. In the unadjusted Cox model, reloading P2Y12 receptor inhibitors was associated with a decreased risk of MACE [HR, 0.35; 95% CI 0.16-0.78; (P = 0.010)] and all-cause death [HR, 0.37; 95% CI 0.14-0.94; (P = 0.036)]. Reloading of P2Y12 receptor inhibitors was associated with a decreased risk of MACE in most of the subgroups.Conclusions In NSTEACS patients already taking P2Y12 receptor inhibitors, we observed a decreased risk of in-hospital MACEs and all-cause mortality and did not observe an increased risk of major bleeding, with reloading. The differential profile in the two groups might influence this association and further studies are warranted.
引用
收藏
页数:11
相关论文
共 50 条
  • [31] P2Y12 Receptor Inhibitors: Integrating Ticagrelor into the Management of Acute Coronary Syndrome
    Crouch, Michael A.
    Colucci, Vince J.
    Howard, Patricia A.
    Spinler, Sarah A.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (09) : 1151 - 1156
  • [32] P2Y12 inhibitors in patients with non-ST-segment elevation acute coronary syndrome: systematic review and network meta-analysis of randomized trials
    Fujisaki, T.
    Kuno, T.
    Briasoulis, A.
    Misumida, N.
    Takagi, H.
    Latib, A.
    EUROPEAN HEART JOURNAL, 2021, 42 : 1213 - 1213
  • [33] Association of Parenteral Anticoagulation Therapy With Outcomes in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Without Invasive Therapy: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project
    Liu, Yuan-Hui
    Fan, Hua-Lin
    Zeng, Li-Huan
    Duan, Chong-Yang
    Chen, Guo
    Chen, Peng-Yuan
    Zhao, Dong
    Liu, Jing
    Hao, Yong-Chen
    He, Wen-Fei
    Tao, Sha
    Wei, Xue-Biao
    Jiang, Lei
    Guo, Wei
    Guo, Yan-Song
    Chen, Wei
    Li, Jun
    Hu, Yun-Zhao
    Li, Wen-Sheng
    Chen, Yi-Yue
    Luo, Jian-Fang
    Zhou, Ying-Ling
    Yu, Dan-Qing
    Han, Ya-Ling
    Tan, Ning
    Chen, Ji-Yan
    He, Peng-Cheng
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 1119 - 1126
  • [34] Do we need P2Y12 inhibitor pretreatment in non-ST elevation acute coronary syndrome?
    De Caterina, Raffaele
    Veneri, Alessia Delli
    REVISTA PORTUGUESA DE CARDIOLOGIA, 2016, 35 (06) : 319 - 321
  • [35] Correction to: Admission fasting plasma glucose is associated with in-hospital outcomes in patients with acute coronary syndrome and diabetes: findings from the improving Care for Cardiovascular Disease in China - Acute Coronary Syndrome (CCC-ACS) project
    Nan Ye
    Lijiao Yang
    Guoqin Wang
    Weijing Bian
    Fengbo Xu
    Changsheng Ma
    Dong Zhao
    Jing Liu
    Yongchen Hao
    Jun Liu
    Na Yang
    Hong Cheng
    BMC Cardiovascular Disorders, 21
  • [36] In-Hospital Bleeding and Mortality in Acute Coronary Syndrome Patients Treated with Tirofiban and Potent P2Y12 Inhibitors
    Akinci, Sinan
    Coner, Ali
    Akbay, Ertan
    Adar, Adem
    Muderrisoglu, Haldun
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2022, 50 (05): : 320 - 326
  • [37] Effect of new p2y12 inhibitors in patients with chronic kidney disease after an acute coronary syndrome
    Deharo, P.
    Pankert, M.
    Bonnet, G.
    Quilici, J.
    Bonnet, J. L.
    Cuisset, T.
    EUROPEAN HEART JOURNAL, 2014, 35 : 1163 - 1163
  • [38] What Is the Rush? Optimizing the Timing of P2Y12 Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes
    Kim, Joseph M.
    Yeh, Robert W.
    Secemsky, Eric A.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2025, 85 (04) : 335 - 338
  • [39] P2Y12 antagonists in non-ST-segment elevation acute coronary syndromes: latest evidence and optimal use
    Norgard, Nicholas B.
    DiNicolantonio, James J.
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2015, 6 (04) : 204 - 218
  • [40] State of the art on pretreatment with oral P2Y12 receptor inhibitors in patients with acute coronary syndrome without ST segment elevation: there is no longer DUBIUS
    Musumeci, Giuseppe
    Annibali, Gianmarco
    GIORNALE ITALIANO DI CARDIOLOGIA, 2021, 22 (09) : 712 - 714